FIVE-YEAR INCIDENCE AND VISUAL ACUITY OUTCOMES FOR INTRAVITREAL THERAPY IN BILATERAL NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
| Autor: | Kelvin Yi Chong Teo, Daniel Barthelmes, Stephanie Young, David Squirrel, Mark C Gillies, Elisa E Cornish, Vuong Nguyen |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
Vascular Endothelial Growth Factor A 0301 basic medicine medicine.medical_specialty Time Factors Visual acuity genetic structures Visual Acuity Angiogenesis Inhibitors Blindness 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Ranibizumab Ophthalmology Age related Treatment intensity medicine Humans Cumulative incidence Aged Retrospective Studies Aged 80 and over business.industry Incidence (epidemiology) Retinal General Medicine Middle Aged Macular degeneration medicine.disease eye diseases Bevacizumab Treatment Outcome 030104 developmental biology chemistry Intravitreal Injections Wet Macular Degeneration 030221 ophthalmology & optometry Female sense organs medicine.symptom business Follow-Up Studies |
| Zdroj: | Retina. 41:118-124 |
| ISSN: | 0275-004X |
| DOI: | 10.1097/iae.0000000000002798 |
| Popis: | To compare treatment intensity and mean visual acuity gains for first- and second-affected eyes with age-related macular degeneration nAMD over 5 years of treatment. The cumulative incidence of second-eye involvement was assessed.We analyzed data from the Fight Retinal Blindness! project database, a prospectively designed registry of "real-world" outcomes from Australia, New Zealand, Switzerland, and Singapore. Patients with bilateral age-related macular degeneration with ≥5 years of follow-up on treatment were included.Six thousand five hundred and forty-two eyes being treated for age-related macular degeneration were tracked from 2005 to 2017. Thousand two hundred and sixty-one patients had bilateral age-related macular degeneration; of whom, 302 had 5 years of follow-up. Of these, 170 patients started treatment for each eye at least 2 months apart. The mean baseline visual acuity of second-affected eyes was significantly higher than that of first-eyes (20/50 + 2 vs. 20/80; P0.01). Second-affected eyes lost a mean of 5.8 (-9.1 to -2.6) logarithm of the minimum angle of resolution letters after 5 years of treatment, whereas the vision of the first-affected eyes remained stable (P = 0.01). Second-affected eyes received fewer injections than the first-affected eyes after the first year of treatment (6.2/year vs. 7.8/year; P0.01) and reactivated earlier (376 vs. 507 days; P = 0.04). The cumulative incidence of second eye involvement was 54% over 5 years.Second-affected eyes received fewer treatments and reactivated earlier. Care should be taken to avoid undertreating second-affected eyes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|